How Much Is Vivus Worth?

By Theodore Cohen:Friday was a big day for Vivus (VVUS). At 2:22 pm, the company announced that the FDA had approved Stendra, also known as Avanafil, a new drug to treat erectile dysfunction. Stendra is a pill that patients take on an as-needed basis 30 minutes before sexual activity. The drug is marketed by Vivus.

Joseph Krueger submits: Before the FDA review panel’s of Vivus’s (VVUS) drug Qnexa, I expressed significant doubt that the panel review would be positive based primarily on the safety issues surrounding one of its ingredients topiramate here.

By Ry Frank:Get ready, because I believe Vivus (VVUS) is set to hit a major upside around mid to late April 2012, which will cause its share price will skyrocket. Vivus is a small company with a rather unexceptional drug pipeline covering diabetes, sleep apnea and erectile dysfunction, which already have many successful treatment courses.

Joseph Krueger submits: This week is a critical time period for Vivus (VVUS) investors, but it should also be interesting for Arena Pharmaceuticals (ARNA) and Orexigen (OREX) investors, as the three companies all have near term FDA panel

By EXPstocktrader:Vivus, Inc. (VVUS) is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigation product in clinical development for the treatment of obesity, Qnexa® is now called Qsymia - with the first of more than a reported dozen-odd names submitted to the FDA being rejected.

By Brian L. Wilson:The up-and-coming drug company Vivus (VVUS) is about to get its complete response letter to the NDA that was submitted, which could finally give us an FDA approval for Qnexa. If you remember, this NDA was delayed back on April 17th for three months.

Jason Chew submits: The success of Orexigen’s (OREX) weight loss drug, Contrave, with the FDA advisory panel highlights an important area in drug development - repositioning. Orexigen accomplished this by combining the off-patent drugs bupropion and naltrexone in a novel, single-pill, fixed-dose formulation.

By Cris Frangold: Vivus (VVUS), a biotechnology company that focuses on obesity, diabetes and male sexual health is up roughly 150% year to date. Vivus has never had any revenues and operating losses since its existence, yet still sports a $2.1 billion market cap. This market cap solely rest on the hope of approval for its obesity medication Qnexa.